Risk factors and classifications of hilar cholangiocarcinoma

Suárez-Muñoz, Miguel Ángel; Fernández-Aguilar, José Luis; Sánchez-Pérez, Belinda; Daga, J.A. Pérez; Garcia-Albiach, Beatriz; Pulido-Roa, Ysabel; Marin-Camero, Naiara; Santoyo-Santoyo, Julio

doi:10.4251/wjgo.v5.i7.132

Cited by 66 publications

(56 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Холангиокарцинома составляет менее 2% всех злока-чественных новообразований человека, при этом она яв-ляется второй по распространенности среди первичных опухолей печени после гепатоцеллюлярного рака [21,23,25,27].…”

Section: хирургия 4 2015unclassified

“…В США ежегодно регистрируется при-мерно 3000 новых случаев опухоли Клатскина. Средний возраст развития болезни 50-60 лет [1,2,13,23,[25][26][27].…”

Section: хирургия 4 2015unclassified

“…У большинства пациентов при выявлении ПСХ заболеваемость холангиокарциномой в течение 2,5 года составляет от 6 до 36%. В связи с тем, что при ПСХ поражаются как внутри-, так и внепеченочные желчные протоки, этот фактор риска относится равно-правно как к внутри-, так и к внепеченочным холангио-карциномам [23][24][25][26][27].…”

Section: хирургия 4 2015unclassified

“…В настоящее время используются различные класси-фикации опухолей Клатскина, каждая описывает кон-кретные аспекты опухоли [25]. Опухоль Клатскина представляет собой первичное злокачественное новообразование, исходящее из внепеченочных желчных протоков и составляющее на сегодняшний день от 50 до 70% всех холангиокарцином.…”

Section: хирургия 4 2015unclassified

See 3 more Smart Citations

View of the problem of Rlatskin tumor

Czhao¹,

Шевченко²,

Zharikov³

2015

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

Ключевые слова: опухоль Клатскина, факторы риска, классификация, диагностика, лечение, прогноз. Klatskin tumorarises from the common hepatic duct and its bifurcation the bile ducts and is the most common primary malignancy of the biliary tree. The location of the tumor and its close relationship with vascular structures at the hepatic hilum have resulted in a low resectability and high rate morbidity and mortality. Improvementof instrumental diagnostics and operative techniquesallowsto performextendedresectionand complexinterventions onthe liver, bile ductsand vascularstructuresat the hepatic hilum. The role ofchemoradiotherapyandphotodynamic therapyis not fullyunderstood. Thus, questions of treatmentandprognosis of the diseaseare remain relevantandrequire further study.

show abstract

Section: хирургия 4 2015unclassified

See 2 more Smart Citations

View of the problem of Rlatskin tumor

Czhao¹,

Шевченко²,

Zharikov³

2015

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

show abstract

“…These methods include multidetector computed tomography, Cholangio-magnetic resonance, percutaneous transhepatic cholangioscopy, positron emission tomography computed tomography and staging by laparoscopy reviewed by Prof. Rotellar et al [6] . Prof. Suarez-Munoz et al [7] have updated the classification/staging systems in HC: There have been several pro- posals to improve the classic Bismuth-Corlette classification, among them the Memorial Sloan-Kettering Center system, the 7 th edition of TNM, and the most complete system so far devised by de DeOliveira et al [2] . Correct preoperative staging is essential to identify the patients who should be operated.…”

Section: Editorialmentioning

confidence: 99%

Hilar Cholangiocarcinoma

Miyazaki

Itoh²,

Kimura³

et al. 2016

Principles of Hepatic Surgery

View full text Add to dashboard Cite

EDITORIALHilar cholangiocarcinoma (HC) is a rare tumor (0.74-1.05 ×100000 inhabitants), representing 3% of gastrointestinal cancers [1,2] . It accounts for 2/3 of the tumors of the biliary tract [1] . Although HC is frequently discussed at surgical scientific meetings and arouses great interest, it has far fewer citations than other HPB cancers and several questions regarding the condition remain unanswered in the medical literature.Untreated, the prognosis of HC is very poor. Surgery is the only therapy that offers the possibility of cure but is technically very complex [1,3] . A few years ago, the number of patients operated and resected was very low, and 5-year survival was mediocre. With recent improvements in the therapeutic strategies applied by multidisciplinary teams comprising radiologists, gastroenterologists, surgeons and oncologists, survival rates in the different series currently range from 25% to 45% [3,4] . A group of experts devoted to HC (pathologists, gastroenterologists, radiologists, surgeons and oncologists) have reviewed and updated every open question in HC in this special issue focusing in the following areas of the management and treatment of patients with HC:Prof. Valls et al [5] has updated diagnostic methods in HC: Imaging methods have improved diagnostic sensitivity and specificity, especially for determining biliary and vascular involvement. These methods include multidetector computed tomography, Cholangio-magnetic resonance, percutaneous transhepatic cholangioscopy, positron emission tomography computed tomography and staging by laparoscopy reviewed by Prof. Rotellar et al [6] . Prof. Suarez-Munoz et al [7] have updated the classification/staging systems in HC: There have been several pro- AbstractHilar cholangiocarcinoma (HC) is a rare tumor. It accounts for 2/3 of the tumors of the biliary tract. Untreated, prognosis is very poor. Surgery is the only therapy that offers the possibility of cure but is technically very complex. With recent improvements in the therapeutic strategies applied by multidisciplinary teams, survival rates in the different series currently range from 25% to 45%. A group of experts devoted to HC (pathologists, gastroenterologists, radiologists, surgeons and oncologists) have reviewed and updated every open question in HC in a special issue. Key words: Cholangiocarcinoma; Hilar; Perihilar; Klatskin; Surgery; Cancer; Review Core tip: Most remarked avances are: imaging methods have improved diagnostic sensitivity and specificity, especially for determining biliary and vascular involvement; there have been several proposals to improve the classic Bismuth-Corlette classification; preand post-operative care; technical aspects trying to obtain a R0 resection: widespread use of liver resection, resection of segment I and venous and arterial resection, refinement of post-operative histology and adjuvant therapies.

show abstract

The association between circulating MicroRNA‐150 level and cholangiocarcinoma

Salem

Ghazala

Gendi

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a rare tumor comprising approximately 3% of gastrointestinal tumors with an overall incidence of less than 2/100 000. It is the second most common primary hepatic malignancy following hepatocellular carcinoma (HCC). 1,2 CCA incidence has been increasing globally during the last decades, where its incidence increases with age. 3 According to the anatomic location, CCA is classified into intrahepatic (IH-CCA) and extrahepatic (EH-CCA) where the later accounts for 80%-90% of all cases. 4 The commonest risk factors for CCA are primary sclerosing cholangitis (PSC), 5 chronic liver disease (including chronic viral hepatitis B and C), 6 and intrahepatic stones (hepatolithiasis). 7 CCA patients remain clinically silent until the advanced stages of the disease. The common clinical feature of EH-CCA is biliary obstruction resulting in painless jaundice, while IH-CCA presents in most cases

show abstract

Risk factors and classifications of hilar cholangiocarcinoma

Cited by 66 publications

References 16 publications

View of the problem of Rlatskin tumor

View of the problem of Rlatskin tumor

Hilar Cholangiocarcinoma

The association between circulating MicroRNA‐150 level and cholangiocarcinoma

Contact Info

Product

Resources

About